Insmed Incorporated (INSM) Discusses 12-Month Results From Ongoing TPIP Open-Label Extension Study in PAH Patients TranscriptSeeking Alpha • 07/16/26
Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial HypertensionPRNewsWire • 07/16/26
EMBARC Announces Its Intention to Collaborate with Insmed on Landmark Interventional Study Evaluating Disease Modification Potential of Brensocatib in BronchiectasisGlobeNewsWire • 06/25/26
Insmed Appoints Samuele Butera as Senior Vice President, General Manager, Global RespiratoryPRNewsWire • 06/23/26
Insmed: Extensive Phase 3 TPIP Program And Revenue Growth In Q1 2026, Strong BuySeeking Alpha • 06/22/26
Insmed Incorporated (INSM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/09/26
Insmed Incorporated (INSM) Presents at RBC Capital Markets Global Healthcare Conference 2026 TranscriptSeeking Alpha • 05/20/26
Insmed Incorporated (INSM) Presents at Bank of America Global Healthcare Conference 2026 TranscriptSeeking Alpha • 05/12/26
Insmed Tanks On Its Most Important Launch; Why Analysts Remain BullishInvestors Business Daily • 05/07/26
Insmed Reports First-Quarter 2026 Financial Results and Provides Business UpdatePRNewsWire • 05/07/26
Insmed and Ty Pennington Team Up to Drive Awareness and Proper Diagnosis of BronchiectasisPRNewsWire • 05/06/26
Insmed to Present Data Across Its Respiratory Portfolio, Including Late-Breaking ARIKAYCE® Results from Phase 3b ENCORE Study, at the American Thoracic Society International Conference 2026PRNewsWire • 05/04/26
Insmed (INSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 04/30/26
Insmed to Host First-Quarter 2026 Financial Results Conference Call on Thursday, May 7, 2026PRNewsWire • 04/23/26
Insmed Ends Brinsupri Development in Skin Disease Post Study FailureZacks Investment Research • 04/08/26